ALB and cardiovascular disorder: These trials included people with type 2 diabetes with and without pre-existing cardiovascular disease, and had composite renal endpoints incorporating two or more of the following (which differed between trials): changes in eGFR/serum creatinine, end-stage renal disease, changes in urine albumin:creatinine ratio (ACR), and/or death from renal causes.